Preclinical Immunogenicity and Efficacy of a Multiple Antigen-Presenting System (MAPSTM) SARS-CoV-2 Vaccine
Open Access
Abstract
Despite the remarkable success of SARS-CoV-2 vaccines, the rise of variants, some of which are more resistant to the effects of vaccination, highlights the potential need for additional COVID-19 vaccines. We used the Multiple Antigen-Presenting System (MAPS) technology, in which proteins are presented on a polysaccharide polymer to induce antibody, Th1, Th17 and CD8+ T cell responses, to engineer a novel vaccine targeting SARS-CoV-2. This vaccine contains a fragment of the spike (S) protein receptor-binding domain (RBD) sequence of the original D614G strain and was used to immunize nonhuman primates (NHP) for assessment of immunological responses and protection against SARS-CoV-2 challenge. The SARS-CoV-2 MAPS vaccine generated robust neutralizing antibodies as well as Th1, Th17 and cytotoxic CD8 T-cell responses in NHPs. Furthermore, MAPS-immunized NHPs had significantly lower viral loads in the nasopharynx and lung compared to control animals. Taken together, these findings support the use of the MAPS platform to make a SARS-CoV-2 vaccine. The nature of the platform also could enable its use for the inclusion of different variants in a single vaccine.Keywords
All Related Versions
This publication has 38 references indexed in Scilit:
- Protection against Staphylococcus aureus Colonization and Infection by B- and T-Cell-Mediated MechanismsmBio, 2018
- Multiplexed Fc array for evaluation of antigen-specific antibody effector profilesJournal of Immunological Methods, 2017
- Capsular Polysaccharide (CPS) Release by Serotype 3 Pneumococcal Strains Reduces the Protective Effect of Anti-Type 3 CPS AntibodiesClinical and Vaccine Immunology, 2016
- Dissecting Polyclonal Vaccine-Induced Humoral Immunity against HIV Using Systems SerologyCell, 2015
- Mouse and human FcR effector functionsImmunological Reviews, 2015
- The FcγR of Humans and Non-human Primates and Their Interaction with IgG: Implications for Induction of Inflammation, Resistance to Infection and the Use of Therapeutic Monoclonal Antibodies2014
- Multiple antigen-presenting system (MAPS) to induce comprehensive B- and T-cell immunityProceedings of the National Academy of Sciences, 2013
- High-throughput, multiplexed IgG subclassing of antigen-specific antibodies from clinical samplesJournal of Immunological Methods, 2012
- A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samplesJournal of Immunological Methods, 2011
- T Cell Responses Are Required for Protection from Clinical Disease and for Virus Clearance in Severe Acute Respiratory Syndrome Coronavirus-Infected MiceJournal of Virology, 2010